Skip to main content
ROCKET PHARMACEUTICALS, INC. logo

ROCKET PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · RCKT ISIN · US77313F1066 LEI · 549300R7VV82YUIN4Y93 US Manufacturing
Open in API
Filings indexed 890 across all filing types
Latest filing 2015-02-18 Director's Dealing
Country US United States of America
Listing US RCKT

About ROCKET PHARMACEUTICALS, INC.

https://www.rocketpharma.com/

Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company that develops gene therapies for rare and devastating diseases. The company's mission is to provide cures by correcting the root cause of disease at the genetic level. It utilizes a multi-platform approach, employing both ex vivo lentiviral (LV) and in vivo adeno-associated viral (AAV) technologies. This strategy allows for the selection of the most suitable platform for specific conditions, with a focus on diseases with high unmet needs, including bone marrow-derived and cardiovascular disorders. Rocket aims to advance a sustainable pipeline of first-in-class investigational genetic therapies for patients.

Recent filings

Filing Released Lang Actions
FORM 3 SUBMISSION
Director's Dealing
2015-02-18 English
FORM 3 SUBMISSION
Director's Dealing
2015-02-18 English
FORM 3 SUBMISSION
Director's Dealing
2015-02-18 English
FORM 3 SUBMISSION
Director's Dealing
2015-02-18 English
AMENDMENT NO.5 TO FORM S-1
Capital/Financing Update Classification · 95% confidence The document is titled 'Amendment No. 5 to Form S-1' and is a registration statement filed with the SEC under the Securities Act of 1933. It includes details about securities registration, underwriting agreements, corporate governance documents, and exhibits related to stock options and loan agreements. Form S-1 is used for initial registration of securities for public offering, which is a capital raising activity. The document is not an annual or quarterly report, audit report, earnings release, or any other financial performance report. It is a regulatory filing related to capital markets and securities registration. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). The document length is over 10,000 characters, indicating it is a full filing, not just an announcement or certification.
2015-02-17 English
Capital/Financing Update 2015
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to the SEC Division of Corporation Finance regarding a request for acceleration of the effective date of a Registration Statement on Form S-1. It references the Securities Act of 1933 and Rules 461 and 460, which pertain to the registration and offering process of securities. The letter is from representatives of underwriters requesting the effective date acceleration for a public offering of common stock and convertible notes. This type of document is related to capital raising activities and financing updates rather than a financial report, earnings release, or other categories. It is not a full report but an update on financing activity. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is short and focused on the financing event, supporting this classification with high confidence.
2015-02-17 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.